Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lorexys
- Development stage
- Phase 2
- Lead developer
- S1 Biopharma, Inc.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lorexys is a fixed-dose combination of bupropion and trazodone being developed by S1 Biopharma for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI) that enhances sexual desire by increasing dopamine and norepinephrine levels in the brain's reward pathways. Trazodone is a serotonin antagonist and reuptake inhibitor (SARI) that, at low doses, acts primarily as a 5-HT2A receptor antagonist, which can help mitigate the anxiety and inhibitory signals that suppress sexual desire. The combination aims to restore the balance between excitatory (dopamine/norepinephrine) and inhibitory (serotonin) neurotransmitter systems involved in sexual response.
- Brand names
- Lorexys
- Other names
- bupropion + trazodonebupropion/trazodone combination
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Lorexys.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lorexys.